Similar articles

• Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.

  Cartwright R, Srikrishna S, Cardozo L, Robinson D. Cartwright R, et al. BJU Int. 2011 Jan;107(1):70-6. doi: 10.1111/j.1464-410X.2010.09508.x. BJU Int. 2011. PMID: 20626389 Clinical Trial.
• In brief: Oxytrol OTC.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2013 Sep 16;55(1425):76. Med Lett Drugs Ther. 2013. PMID: 24662958 No abstract available.
• Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.

  Costantini E, Lazzeri M. Costantini E, et al. Eur Urol. 2010 Jan;57(1):152-3. doi: 10.1016/j.eururo.2009.04.046. Epub 2009 May 7. Eur Urol. 2010. PMID: 19446952 No abstract available.
• Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.

  Staskin DR, Robinson D. Staskin DR, et al. Expert Opin Pharmacother. 2009 Dec;10(18):3103-11. doi: 10.1517/14656560903451682. Expert Opin Pharmacother. 2009. PMID: 19954278 Review.
• Oxybutynin gel for the treatment of overactive bladder.

  Gomelsky A, Dmochowski RR. Gomelsky A, et al. Expert Opin Pharmacother. 2012 Jun;13(9):1337-43. doi: 10.1517/14656566.2012.688953. Expert Opin Pharmacother. 2012. PMID: 22607010 Review.